Amerikaanse aandelen « Terug naar discussie overzicht

intercloud--icld

429 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 ... 18 19 20 21 22 » | Laatste
[verwijderd]
0
quote:

Jager63 schreef op 19 november 2015 15:14:

Goede derde kwartaalcijfers en vooruitzichten!
net thuis jan .
Zal straks even verdiepen
Zag icld en vrx toch wel aardig groen staan op de app zojuist.
Ff eten douchen eten de Kids naar bed dan kom ik weer terug eten kijken wat de koers dan doet
Eet ze
[verwijderd]
0
Mooi herstel van Intercloud, maar we komen van diep. Verwacht morgen nog een plus van 10%. Heb wel de helft verkocht, zodat ik niet meer in het rood sta. Valeant iets te snel verkocht.
[verwijderd]
0
quote:

Jager63 schreef op 19 november 2015 19:11:

Mooi herstel van Intercloud, maar we komen van diep. Verwacht morgen nog een plus van 10%. Heb wel de helft verkocht, zodat ik niet meer in het rood sta. Valeant iets te snel verkocht.
bij Intercloud ben ik nog rood bij vrx loopt ie lekker op zo +10 dollar al vandaag
[verwijderd]
0
Jager wat denk jij van vrx op dit moment een ritje doen of blijven zitten nu
Gaat erg hard deze twee dagen
[verwijderd]
0
Advies geven is gevaarlijk, want ik neem nogal snel mijn winst. Geweldige stijging de afgelopen dagen, dus ik heb al een paar ritjes gemaakt. Maar voor hetzelfde geld gaat de stijging nog een paar dagen door.
[verwijderd]
0
Why Valeant Pharmaceuticals Intl Inc Was Incentivized to Climb Higher Today
The drug company is making efforts to keep employees around during the turbulent times.

What: Valeant Pharmaceuticals (NYSE:VRX) was up about 15% today after climbing 3.2% yesterday. The only news seems to be a report from Reuters that the company will offer cash and stock to incentivize employees to stick around. The company may also be getting a boost from Citi Credit Research initiating coverage with an overweight.

So what: The drug company has had a tumultuous month or so -- outlined here -- so it's not too surprising that employees might consider leaving. Losing employees isn't the end of the world, but it's likely cheaper to offer incentives to stay than to lose their corporate memory and have to train new employees.

Reuters reports that "about 70 Valeant employees in key positions below the executive level are receiving cash and stock to stay with the company" and that more U.S. staff are likely to get incentives in the coming weeks. Outside the U.S., the fear of a mass exodus isn't as much of a worry because Valeant goes by other names.

Now what: Retaining employees is clearly a prudent move for Valeant to make, helping ensure the long-term health of the company. Whether it's worthy of a double-digit gain is debatable, but given all that's happened with Valeant, it was almost inevitable that the valuation would overshoot on the low side before rebounding.

VRX Chart

As you can see on the chart, there have been a few rebounds before, so we won't know for a little while whether Tuesday was the low, but it's clear investors have a long way to go before reaching recent highs.

Brian Orelli has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
[verwijderd]
0
www.fool.com/investing/general/2015/1...

vind het toch wel 2 heerlijke fondsen,
leuk voor de ritjes.
en kan in de avond wat doen ,nu komt er tot de kerst niets meer van om overdag wat te doen,
drukte op het werk ivm kerst en eindejaars drukte
[verwijderd]
0
3 Small Company Stocks with Dropping Short Interest: InterCloud Systems, Inc (ICLD), Builders FirstSource, Inc. (BLDR), LifeLock, Inc. (LOCK)
BY MICHAEL WELCH • NOVEMBER 20, 2015
Short interest ratio is calculated as short interest divided by the stock’s average daily trading volume. It indicates how many days it would take for short sellers to purchase shares required for already contracted sales (called ‘covering the short position’) if the stock price increases against expectations of decline.

Looking at short interest is a good way to grasp the market’s sentiment in relation to a particular stock. High short interest ratios imply investors are expecting for a stock’s price to fall.

A low short interest ratio means that not many investors think the stock’s price will decline. This shows optimism — or at the very least a lack of pessimism — by investors. However, a high short interest ratio can have a paradoxically beneficial effect on the stock as well. Should a stock with a high short interest ratio begin to advance, the short sellers may panic and begin buying the stock to cover their shorts. The lower the stock price, the more the short sellers profit; as the stock price climbs, they lose money. This panic buying by large numbers of short sellers may result in a so-called short squeeze and take the stock price much higher.

As of October 30, 2015, short interest for InterCloud Systems, Inc (ICLD) stood at 1164111 shares, a decrease compared to 1347099 shares on October 15, 2015. This short interest comprises 5.8 percent of the entire float. Short interest ratio now stands at 8 at the average volume of 154410 shares.

According to the latest short-interest data for the two-week period ended October 30, 2015, short interest for the stock of Builders FirstSource, Inc. (BLDR) decreased from 5455608 shares at the end of the settlement date of October 15, 2015 to 4706183 shares, marking a drop of -749425 shares. The current short interest accounts for 7.5 percent of the company’s total outstanding common shares and the days-to-cover short interest ratio, on the other hand, is 5 as of October 30, 2015, assuming average daily trading volume of 988251 shares.

Short interest for the shares of LifeLock, Inc. (LOCK) dropped -14.3 percent from 13600195 shares on October 15, 2015 to 11659153 shares on October 30, 2015. Investors have taken short positions on 13.5 percent of the total common shares of the stock that are floating on the exchange. The days-to-cover short interest ratio is now at 4 days. It is based on average daily trading volume of 2715114 shares.
[verwijderd]
0
Ben het met je eens, zijn allebei leuke fondsen voor de daghandel. Speel wel kort op de bal en bekijk per dag mijn kansen. Verder leuk om 's avonds nog iets anders te doen dan televisie kijken,
[verwijderd]
0
Heb ze allebei meegenomen het weekend in.
Ik twijfelde teveel .
Misschien een slechte zet.
Maar dat zien we maandag wel weer.
Fijn weekend
[verwijderd]
0
Intercloud heb ik nog, maar Valeant veel te vroeg weggedaan. Maandag stap ik daar weer in.
[verwijderd]
0
Zelfs deze week (woensdag) nog 50 st. verkocht voor 75 dollar per aandeel, maar dat is het voor- en/of nadeel van daghandel. Per definitie ben je altijd te vroeg of te laat.
[verwijderd]
0
Maar de afgelopen weken sta ik per saldo met Valeant in het groen. Echter niet veel; dat moet beter kunnen. Uitdaging voor de komende week!
[verwijderd]
0
Ff maandag afwachten
als er weer een bericht is zal ik hem plaatsen.
Je genoeg niet in het Nederlands.
Hoop dat je het Engels een beetje kan ontcijferen
[verwijderd]
0
Van Intercloud krijg ik de nieuwsbrief vanaf komende week. Hiervoor kun je op hun website een verzoek doen. Engels is voor mij geen probleem. Een van de voordelen als je wat langer hebt doorgeleerd.
[verwijderd]
0
Ook bij Valeant de nieuwsbrief aangevraagd. Ze zijn wel verwikkeld in een grote fraudezaak, dus wel een beetje oppassen. Op internet kun je alle details, aangaande deze affaire, vinden.
[verwijderd]
0
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Traps in Misleading Lawsuit with Intuit Inc. (NASDAQ:INTU), Stage Stores Inc. (NYSE:SSI)
NOVEMBER 21ST, 2015 DEVON LEFTOVICH BUSINESS NEWS 0 COMMENTS

Rosen Law Firm publicized that it has filed of a class action lawsuit against Valeant Pharmaceuticals International, Inc. (NYSE:VRX) [Detail Analytic Report] on behalf of buyers of securities during February 28, 2014 to October 21, 2015, dates inclusive.

According to the lawsuit, during the Class Period, Defendants issued materially false or misleading statements to shareholders and failed to reveal that the firm had deficient internal controls, the firm had a relationship with a network of specialty pharmacies used to increase Valeant’s sales of its high-priced drugs; the use of specialty pharmacies left Valeant vulnerable to increased regulatory risks, Defendants were under government scrutiny for its financial support programs for patients, pricing decisions and the distribution of its products, the firm faced the risk of scrutiny over its price increases, without using specialty pharmacies, financial performance of the firm would be negatively impacted, without using specialty pharmacies, the firm’s Class Period performance would have been negatively impacted, Valeant’s true relationship with Philidor and the expand of that relationship, Valeant controlled Philidor, Valeant’s subsidiary KGA had a secured lien interest on Philidor’s ownership, Defendants were engaged in a scheme to manipulate stock price of the firm.

As a result, public statements of Valeant were materially false or misleading and lacked a reasonable basis at all relevant times. When the truth revealed, the lawsuit claims that shareholders suffered damages.

Intuit Inc. (NASDAQ:INTU) [Detail Analytic Report] announced its fiscal Q1 loss of $31 million in its fiscal. Intuit revealed that it had a loss of 11 cents a share. Earnings, revised for one-time gains and costs, were 9 cents a share. The results exceeded Wall Street outlooks. The average estimate of experts polled by Zacks Investment Research was for a loss of 3 cents a share. Intuit declared its revenue of $713 million in the quarter, which also beat Street forecasts. According to analysts polled by Zacks expected $669.6 million.

For the current quarter completing in February, Intuit expects its earnings to be 17 to 20 cents a share. The firm reported it expects revenue in the range of $880 to $900 million for the fiscal second quarter. Intuit expects full-year earnings in the range of $3.45 to $3.50 a share, with revenue ranging from $4.53 to $4.6 billion. Shares of Intuit have increased almost 6 percent since the starting of the year.

Brad Smith, President and CEO of Intuit stated that they started the fiscal year the same way they ended the last, with strong momentum across their businesses as their intense focus on their international cloud strategy takes shape. They topped their subscriber and financial targets in the period and have raised their earnings a share guidance for the fiscal year based on these initial strong results and their acceleration of share buybacks in the period.

Stage Stores Inc. (NYSE:SSI) [Detail Analytic Report] declared that Board of Directors of the firm has announced a quarterly cash dividend of 15 cents a share on the firm’s common stock, to be paid on December 16, 2015 to investors of record at the close of trading session on December 1, 2015.

Stage Stores also announced its fiscal Q3 loss of $10.2 million. Stage Stores reported it had a loss of 32 cents a share. The results missed Wall Street outlooks. Stage Stores revealed its revenue of $351.6 million in the quarter, also missing Street forecasts. Shares of Stage Stores have tumbled 56 percent since the starting of the year.

Michael Glazer, President and CEO of Stage Stores stated that their Q3 results were negatively impacted by stores located in geographies which were pressured by oil and gas and a devalued peso. Stores outside of those areas achieved a flat comp for the period. Based on these results and their expectation that these challenges will continue in the near term, they are guiding their comp sales to a range of -2% to -4% for the Q4 and adjusted earnings per diluted share to $0.70 to $0.80 for the fiscal year. They will manage their business with discipline around inventory control, implement additional cost cuts and maintain their focus on improving store productivity and driving online sales.
[verwijderd]
0
Maxim Remains Sidelined On Valeant Pharmaceuticals Intl Inc (VRX) Following Orkambi Europe Approval
SHARE ON:
Jason Cohen, Editor — November 20, 2015, 5:18 PM EDT
In a research note issued Friday, Maxim analyst Jason McCarthy reiterated a Hold rating on shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), after the company announced that Orkambi, has been approved in Europe for the treatment of Cystic Fibrosis patients 12 and older who are homozygous (two copies) for the F508del mutation. No price target was provided.

McCarthy observed, “Orkambi approval and a successful launch in both the U.S. (underway) and Europe (coming soon) is already factored into our model. We also assume that VX-661/ivacaftor will be successful in the heterozygous population. However, the question that still remains is: What is the risk of failure in heterozygotes? Multiple phase III studies should have data in 2016. Will it be positive? We’ll see, but for now we remain HOLD rated while we await data.”

The analyst continued, “With approval in the U.S. (July 2, 2015) and expected in Europe (early 2016), the focus is now on the launch trajectory. With up to 28,000 F508del homozygotes worldwide (20,000 combined in the U.S. and Europe), uptake could be impacted by the volume of patients, centers, and doctors creating an initial bottleneck. However, in 3Q15, Vertex has already treated 3,000 patients in the U.S., which suggests, at this rate, the first 8,500 U.S. CF patients eligible for Orkambi could be on the drug within six months”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason McCarthy has a total average return of -2.2% and a 40% success rate. McCarthy is ranked #2983 out of 3857 analysts.

Out of the 20 analysts polled by TipRanks, 13 rate Valeant Pharmaceuticals stock a Buy, 6 rate the stock a Hold and 1 recommends s Sell. With a return potential of nearly 85%, the stock’s consensus target price stands at $168.24.
[verwijderd]
0
HEDGE FUNDS-NEWS
Hedge Funds Are Dumping Valeant Pharmaceuticals Intl Inc (VRX); Should You?
Published on November 20, 2015 at 4:20 pm by ALEXANDR OLEINIC in Hedge Funds,News
3
Shares21
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the government. The 13F filings show the funds’ and investors’ portfolio positions as of September 30. In this article we will look at what those investors think of Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

Teva Pharmaceuticals TEVA Drugs

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was in 88 hedge funds’ portfolio at the end of September. VRX has seen a decrease in activity from the world’s largest hedge funds lately. There were 98 hedge funds in our database with VRX positions at the end of the previous quarter.

Follow Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Enter Your Email
Get Email Alerts
If you’d ask most shareholders, hedge funds are perceived as slow, old investment vehicles of yesteryear. While there are over 8000 funds with their doors open today, Experts at hedge fund tracking site Insider Monkey look at the bigwigs of this group, about 700 funds. These hedge fund managers have their hands on bulk of all hedge funds’ total asset base, and by keeping track of their top picks, Insider Monkey has deciphered numerous investment strategies that have historically exceeded the market. Insider Monkey’s small-cap hedge fund strategy surpassed the S&P 500 index by 12 percentage points per year for a decade in their back tests.

With all of this in mind, let’s take a glance at the new action regarding Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

How are hedge funds trading Valeant Pharmaceuticals Intl Inc (NYSE:VRX)?

Heading into Q4, a total of 88 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -10% from one quarter earlier. With hedgies’ sentiment swirling, there exists a few key hedge fund managers who were boosting their holdings substantially.

When looking at the hedgies followed by Insider Monkey, Pershing Square, managed by Bill Ackman, holds the biggest position in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Pershing Square has a $3.47 billion position in the stock, comprising 24.9% of its 13F portfolio. The second-largest stake is held by ValueAct Capital, led by Jeffrey Ubben, holding a $2.67 billion position; the fund has 15.6% of its 13F portfolio invested in the stock. Some other hedgies that are bullish consist of John Paulson’s Paulson & Co, Stephen Mandel’s Lone Pine Capital and Glenn Greenberg’s Brave Warrior Capital.

Because Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has faced declining sentiment from the entirety of the hedge funds we track, it’s safe to say that there was a specific group of hedgies that slashed their full holdings at the end of the first quarter. It’s worth mentioning that Barry Rosenstein’s JANA Partners sold off the largest position of the 700 funds tracked by Insider Monkey, worth about $298.3 million in stock, and Joshua Kaufman and Craig Nerenberg of Brenner West Capital Partners was right behind this move, as the fund dumped about $129.8 million worth of shares. These moves are intriguing to say the least, as total hedge fund interest fell by 10 funds at the end of the third quarter.

Let’s also examine hedge fund activity in other stocks similar to Valeant Pharmaceuticals Intl Inc (NYSE:VRX). We will take a look at Kinder Morgan Inc (NYSE:KMI), Abbott Laboratories (NYSE:ABT), ConocoPhillips (NYSE:COP), and Danaher Corporation (NYSE:DHR). This group of stocks’ market valuations are similar to VRX’s market valuation.
429 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 ... 18 19 20 21 22 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
874,67  -9,40  -1,06%  17:41
 Germany40^ 17.759,20 -1,48%
 BEL 20 3.796,92 -1,47%
 Europe50^ 4.913,06 -1,43%
 US30^ 37.798,24 +0,26%
 Nasd100^ 17.706,67 +0,07%
 US500^ 5.050,99 -0,20%
 Japan225^ 38.398,62 -0,77%
 Gold spot 2.385,86 +0,11%
 EUR/USD 1,0623 -0,02%
 WTI 85,06 0,00%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

Avantium +5,54%
DSM FIRMENICH AG +1,74%
FASTNED +1,65%
B&S Group SA +1,45%
Arcadis +1,35%

Dalers

ArcelorMittal -6,62%
Aperam -6,61%
JUST EAT TAKE... -4,54%
SBM Offshore -4,04%
RANDSTAD NV -3,63%

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront